Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupXSWX:MOVE +1.30%91 Return-on-Tangible-Equity is 18.48% as of Dec. 2025, which is 38% below its 10-year median of 30.00. GuruFocus rates XSWX:MOVE with a GF Score™ of 91/100 and a GF Value™ of CHF168.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Medacta Group ranks better than 87.62% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medacta Group's annualized net income for the quarter that ended in Dec. 2025 was CHF66.1 Mil. Medacta Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was CHF357.8 Mil. Therefore, Medacta Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 18.48%.
The historical rank and industry rank for Medacta Group's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:MOVE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 18.45 Med: 30 Max: 75.45
Current: 26.29
During the past 11 years, Medacta Group's highest Return-on-Tangible-Equity was 75.45%. The lowest was 18.45%. And the median was 30.00%.
XSWX:MOVE's Return-on-Tangible-Equity is ranked better than 87.62% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs XSWX:MOVE: 26.29
Medacta Group (XSWX:MOVE) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medacta Group Return-on-Tangible-Equity Related Terms
Medacta Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medacta Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MOVE vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Medacta Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medacta Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.48% mean?
Medacta Group (XSWX:MOVE) has a Return-on-Tangible-Equity of 18.48% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medacta Group and its competitors. This is 38% below median its historical median of 30.00. Over the past decade, Medacta Group's Return-on-Tangible-Equity has ranged from 18.45 to 75.45. According to the industry distribution chart, Medacta Group ranks #94 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 12.4%.
Is Medacta Group's Return-on-Tangible-Equity too high?
Medacta Group's current Return-on-Tangible-Equity of 18.48% is 38% below median its 10-year median of 30.00. Over the past 10 years, this metric has ranged from a low of 18.45 to a high of 75.45. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. Medacta Group's value of 18.48% is 357.4% above this industry median. Based on the distribution chart, Medacta Group ranks #94 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #94 out of 759 companies for Return-on-Tangible-Equity. This places Medacta Group in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.04. Medacta Group's value of 18.48% is 357.4% above this benchmark. Historically, Medacta Group's own Return-on-Tangible-Equity has ranged from 18.45 to 75.45 over the past decade. While the company's 10-year median is 30.00 vs. the industry median of 4.04, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current Return-on-Tangible-Equity of 18.48% is 357.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current Return-on-Tangible-Equity is 18.48%, which is 38% below median its own 10-year median of 30.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (XSWX:MOVE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF168.33, compared to a current price of CHF139.80 — trading 16.9% below its estimated fair value. The current Return-on-Tangible-Equity is 18.48%, which is 38% below median its 10-year median of 30.00 and 357.4% above the Medical Devices & Instruments industry median of 4.04. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medacta Group (XSWX:MOVE), the current Return-on-Tangible-Equity is 18.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (XSWX:MOVE) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of CHF139.80 is trading 16.9% below its estimated GF Value™ of CHF168.33.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for XSWX:MOVE:
Return-on-Tangible-Equity: 18.48% (38% below median its 10-year median of 30.00)
GF Value™: CHF168.33 vs. price of CHF139.80 (16.9% below fair value)
Industry Position: 357.4% above the Medical Devices & Instruments median (#94 of 759)
No single metric tells the full story. See the XSWX:MOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score
Get the complete analysis for XSWX:MOVE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOVE has been successfully added to your 
